Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Edward Lifesciences Corporation (“Edwards”) (NYSE: EW) common stock between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”).
The Class Period begins on February 6, 2024, when Edwards issued their fourth quarter results. In connection with its results, the company published a press release, highlighting, in pertinent part, the significant progress that was made by the company’s core product - Transcatheter Aortic Valve Replacement (“TAVR”) - stating that “Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent.”
The complaint alleges that, throughout the Class Period, Defendants provided overwhelmingly positive statements to investors related to the growth of the company's core product, TAVR, while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Edwards’ TAVR platform. Specifically, Edwards’ claims and confidence relied far too heavily on their perceived ability to engage the claimed low-treatment-rate population of patients and an overestimation of the desire for hospitals and other care facilities to continue to utilize and otherwise commit resources to the TAVR procedures over newer, innovative treatment alternatives.
Current Status of Case:
On September 19, 2025, the Court granted in part and denied in part Defendants’ Motion to Dismiss the Amended Complaint. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.